These most prominently include receptor tyrosine kinase (RTK) signalling through the Ras–MAPK and PI3K–AKT–mTOR pathways, Wnt signalling and sonic hedgehog (SHH) signalling, along with the ...

We are a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Our company was ...

The results demonstrate that compared to avutometinib alone, the FAK inhibitor/avutometinib combination inhibits RAS/MAPK pathway signaling more deeply while also blocking key adaptive resistance ...

In particular, I explore pharmacological targeting and characterization of upstream-driven feedbacks of MAPK pathway. I study and characterize the response to KRAS G12C, SOS1 and SHP2 inhibitors alone ...

We are a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Our company was ...

Erasca will also present potential first-in-class examples of direct SMP complex inhibitors, representing a new approach to block the RAS/MAPK pathway SAN DIEGO, March 25, 2025 (GLOBE NEWSWIRE ...

SAN DIEGO, March 25, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for ...